drugset / Trial / NCT02283359
Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to see whether the combination of selinexor (KPT-330) and irinotecan can help people with esophageal or stomach cancer. Researchers also want to find out if the combination of selinexor (KPT-330) and irinotecan is safe and tolerable.
Timeline
- Start
- 2014-12
- Primary completion
- 2015-12
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 125 mg/m2 | Intravenous |
| Subject | Selinexor | Other / unclassified | 25 mg/m2 | Oral |
| Subject | Selinexor | Other / unclassified | 40 mg/m2 | Oral |
| Subject | Selinexor | Other / unclassified | 50 mg/m2 | Oral |
| Subject | Selinexor | Other / unclassified | 65 mg/m2 | Oral |